InxMed Raised $15 million in Series B+ Financing to Advance Innovative Therapies to Drug-resistant Cancers
NANJING, China, May 8, 2022 /PRNewswire/ — InxMed Co., Ltd, a clinical-stage biotechnology company dedicated to developing innovative therapies targeting stroma…